LIFECORE BIOMEDICAL, INC. Gain on Business Interruption Insurance Recovery
LIFECORE BIOMEDICAL, INC. (LFCR) reported Gain on Business Interruption Insurance Recovery of $0 for the 3-month period ending 2020-08-30, per its 10-Q filed 2020-10-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainOnBusinessInterruptionInsuranceRecovery · last filed 2023-03-16
- LIFECORE BIOMEDICAL, INC. gain on business interruption insurance recovery for the quarter ending 2020-08-30 was $0.00, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. gain on business interruption insurance recovery for the quarter ending 2020-05-31 was $0.00.
- LIFECORE BIOMEDICAL, INC. gain on business interruption insurance recovery for the quarter ending 2020-02-23 was $0.00.
- LIFECORE BIOMEDICAL, INC. gain on business interruption insurance recovery for the quarter ending 2019-11-24 was $600.00K.
- LIFECORE BIOMEDICAL, INC. gain on business interruption insurance recovery for fiscal 2020 was $3.00M.
| Period end | Gain on Business Interruption Insurance Recovery 3 month | Gain on Business Interruption Insurance Recovery 6 month | Gain on Business Interruption Insurance Recovery 9 month | Gain on Business Interruption Insurance Recovery 12 month |
|---|---|---|---|---|
| 2020-08-30 | $0.00 10-Q · filed 2020-10-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $600.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-05-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $600.00K derived: sum of 3 quarters · filed 2023-03-16 | $3.00M 10-K/A · filed 2023-03-16 |
| 2020-02-23 | $0.00 10-Q · filed 2020-04-03 | $600.00K derived: sum of 2 quarters · filed 2021-01-07 | $3.00M 10-Q · filed 2020-04-03 | |
| 2019-11-24 | $600.00K 10-Q · filed 2021-01-07 | $3.00M 10-Q · filed 2021-01-07 | ||
| 2019-08-25 | $2.40M 10-Q · filed 2020-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |